The Global Glycomics Market was valued at USD 1.63 Billion in 2022 and is projected to reach USD 3.90 Billion by 2030, registering a CAGR of 14.50% for the forecast period 2023-2030.
The study of the structure, biology, and function of saccharides which are found widely in nature and are also thought to be glycans is known as glycomics or glycobiology. Glycans are present in every living thing. A rapidly developing biological field of interest for many disciplines, including basic research, biotechnology, and biomedicine, is glycobiology. Glycomics instrument technological advancements are one of the main factors propelling the global market. The industry is expanding as a result of growing government investment in research as well as pharmaceutical and biotechnology companies' growing emphasis on developing novel drugs. Additionally, the market is expanding as a result of the increased attention being paid to glycobiology research studies. The market for glycomics has experienced rapid growth due to an increased focus on glycobiology research. New tool development has been made possible by large investments in this field by academic researchers. Innovations in chemical and biochemical research, such as mass spectrometry (MS) and high-performance liquid chromatography (HPLC), have led to advancements in processes like protein characterizations. Results from these methods are highly sensitive and fast.
- 2022: USD 1.63 Billion
- 2030: USD 3.90 Billion
- CAGR (2023-2030): 14.50%
Drivers : Government program to encourage and fund research and development
Glycomics instrument technological advancements are one of the main factors propelling the global market. The industry is expanding as a result of growing government investment in research as well as pharmaceutical and biotechnology companies' growing emphasis on developing novel drugs. Furthermore, an increasing emphasis on glycobiology research studies is also fueling the market's expansion. Other businesses in this industry are seeing profitable opportunities in developing nations. In addition, we are seeing advances in technology as a result of government investments in research and pharmaceutical companies' and biotechnology companies' drug development efforts. Furthermore, there is a growing interest in glycomics and proteomics research studies, which is anticipated to drive market expansion in the near future. Numerous institutions have initiated scholarly investigations aimed at creating novel glycomics and glycobiology instruments. Innovations in chemical and biochemical research, such as mass spectrometry (MS) and high-performance liquid chromatography (HPLC), have led to advancements in processes like protein characterizations. Results from these methods are highly sensitive and fast. The demand for medications to treat a number of serious chronic illnesses is predicted to rise, which will fuel the growth of the glycomics markets.
For instance, in April 2021, Bridge Bio Pharma, Inc. and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centers of Excellence, today announced a collaboration to translate scientific research in glycomics into potential treatments for patients with genetic diseases.
Extension of Universities and Research Centers to Encourage Market Expansion
The global market is anticipated to be driven by factors such as the expansion and advancement of academic and research institutions studying glycomics, which has numerous applications in the quick development of drugs, vaccines, and precision medicines. Revenue streams are created through expanding partnerships between research institutions and important market participants to support biomedical and biochemistry research activities. Manufacturers in the global glycomics market can grow by extending their contact with research organizations in the pharmaceutical industry to outsource research and development tasks in order to stay ahead of the competition. The global glycomics market is driven by an increase in the cooperation between industry players and research institutions to study proteomics and glycomics in order to find treatments for genetic diseases. The next generation of glycomics scientists and technicians is being trained in universities and research facilities. The glycomics market is expanding and innovating thanks to this new talent entering the field. To develop and market new glycan-based products and services, research centers and universities are working with industry partners. This partnership is facilitating the faster and more effective release of new glycomics innovations onto the market.
For instance, in November 2023, according to Massachusetts Institute of Technology, Glyco enthusiasts from MIT and beyond recently gathered in Bartos Theatre to enjoy presentations of the latest advancements in glycobiology research.
April 2022, IonSense Inc., the innovator of ambient DART (Direct Analysis in Real Time) ionization technology, announces that it has been acquired by Bruker Corporation. The deal provides IonSense with the financial investments to ramp up development of the DART ionization source technology and increase efforts in developing applications in the applied markets, including food analysis and forensics.
October 2022, Millions of lives are set to be changed for the better thanks to a landmark deal between Griffith University and Swiss-based company LimmaTech Biologics AG to develop a world-first gonorrhoea vaccine. Researchers from Griffith’s Institute for Glycomics have developed a suite of vaccine technologies for the prevention of gonorrhoea, and potentially other diseases.
Restraint : High cost of tools is restraint the growth of market
For some end users, the glycomics process may be prohibitively expensive or technically too complicated to use. A lot of relatively expensive equipment is used in glycomicomics research. Glycomics is also a complicated topic because carbohydrates have a wide variety of structural variations and are frequently linked in branches. Adoption of glycobiology is hampered by the high cost of instruments and products such as mass spectrometers, glycan analysis kits, enzymes, reagents, and carbohydrates. Glycobiology tool development is a costly endeavor, made even more so by strict laws and regulations. Glycans are identified and measured with the aid of mass spectrometers. These can run into the hundreds of thousands of dollars or more, making them an expensive but necessary tool for glycomics research. Glycan-protein interactions are investigated using glycan microarrays. Although they can be very costly, costing thousands of dollars per array, they are also indispensable tools for glycomics research. The sequence of glycans is ascertained by glycan sequencing machines. They can be extremely costly, costing hundreds of thousands of dollars or more, but they are also vital tools for glycomics research. Research on glycomics may be challenging for scientists due to the high cost of these instruments, particularly in developing nations. This may impede the creation of new glycan-based goods and services as well as slow the rate of innovation in the glycomics industry, overall due to this factor, hinder the growth of glycomic market.
For instance, in October 2022, according to Emory Glycomics and Molecular Interactions Core, the prices of glycomic analysis, ECMIC services average prices between $ 100 to $ 600 and unassisted equipment average pieces between $ 10 to $ 300.
Challenges : Lack of skilled workforce is challenge for market.
A major obstacle is the dearth of qualified personnel conducting glycobiology research and carrying out the procedure. This is a risky, time-consuming, and expensive procedure. Not even the employees who deal with the glycobiology products are in great numbers. The market's largest barrier is this factor. One of the main obstacles to the glycomics market's expansion is the lack of a skilled labor force. Research and development in glycomics are a complex and relatively new field that requires specialized knowledge and skills. Globally, there is a dearth of competent workers in the glycomics industry, which is impeding the market's expansion. The rate of innovation in the field of glycomics is being hindered by a shortage of skilled labor. Without access to a larger pool of skilled workers, researchers are unable to develop new glycan-based products and services as quickly as they could. The glycomics market's companies are having trouble growing because of a lack of skilled labor. Because they are unable to locate the qualified labor they require, businesses are unable to grow and enter new markets. It is becoming more expensive to develop new glycan-based products and services due to a shortage of skilled workers. Increasing wages is necessary for companies to draw and keep skilled workers, which drives up development costs.
Opportunities : Application of glycomic in precision medicine.
The field of precision medicine has expanded quickly in recent years. Pharma and biotech companies are investing heavily in the development of targeted drugs that are intended for use in a particular patient population. Complex biomolecules and sugars found on the surface of cells are involved in a number of functions, such as cell recognition and communication. These are important mechanisms in autoimmune disorders, bacterial and viral infections, and inflammation. A novel approach to healthcare called "precision medicine" attempts to customize care for each patient according to their biological makeup and other traits, including genetics. Glycomics holds promise for the development of novel diagnostics and tools in precision medicine. Glycan biomarkers, for instance, can be used to determine which patients are most likely to respond to a particular cancer treatment, diagnose cancer early, and identify patients who are at risk of developing specific diseases. Glycan biomarkers can be used to identify patients who are most likely to progress quickly and to diagnose Alzheimer's disease early. The glycomics market is seeing new growth opportunity due to the increasing interest in precision medicine. Businesses that are creating tools and diagnostics for precision medicine based on glycomics will stand to gain from this trend.
|Market Size in 2022
|USD 1.63 Billion
|Market Forecast in 2030
|USD 3.90 Billion
|Compound Annual Growth Rate (CAGR)
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By Application, By End-Use & By Region
|2018 - 2022
|2023 - 2030
Segment Analysis of the Glycomics Market
The Glycomics Market is segmented by product, application, end-use and region.
By Product: The Enzymes segment held the largest market share in 2022
By product is sub segmented into enzymes, kits, reagents, instruments. The enzymes segment accounted for highest market share 30% in global glycomics market for 2022. Some of the factors driving the market's expansion include the extensive use of enzymes in glycan-based research, diagnostics, and drug discovery. Numerous studies show that these enzymes are epigenetically regulated in different types of cancer cells, leading to the formation of glycan structures, which are one of the main ways cancerous cells evade the host's immune system. More effective and targeted enzymes for glycomics applications have been developed thanks to developments in protein modification technologies and enzyme engineering. These developments have broadened the use of enzymes in glycan-related production and research.
On the other hand, the instrument segment has the significant market share over the forecast period, due to its rapid expansion is fueled by the growing use of instruments in medication discovery and diagnostic testing. Further supporting market expansion are technical developments in terms of accuracy and turnaround time, as well as growing efforts by industry participants to introduce innovative glycan-based instruments.
By Application: The drug discovery and development segment was the leading segment in 2022
By application, which is divided into drug discovery & development, diagnostics. The drug discovery and development segment accounted for largest share 43% in global glycomics market for 2022. This is mainly because there are more R&D projects being undertaken and the government is investing more money in glycomics and proteomics research. Novel drug targets can now be identified by utilizing sophisticated glycan profiling methods and analytical techniques, which have made possible by advances in glycobiology research. Additionally, it is anticipated that increased cooperation among industry participants to comprehend the function of glycan in the creation of treatments for diverse illnesses will foster the expansion of this market segment.
On the other hand, the diagnostics segment is anticipated to expand over the forecast period, Growth in this market is expected to be driven by elements like the high frequency of chronic illnesses, the growing need for personalized treatment, and developments in glycan analysis technologies. The detection specificity of glycan-based biomarkers was enhanced by developments in glycan analysis, including lectin-based assays, mass spectrometry, and glycan microarrays.
By End-Use : The Academic & Research Institute segment was the leading segment in 2022
By end-use, which is divided into academic & research institute, pharmaceutical & biotechnology companies. The Academic & Research Institute segment accounted for largest share 38.2% in global glycomics market in 2022. This significant portion can be ascribed to research centers' widespread use of glycan structure data analysis. Another reason driving the segment's growth is the growing popularity of the glycobiology field for training and education. Furthermore, a variety of uses for glycomics products in biomedical research, drug development, immunology, cell biology, and biochemistry are anticipated to spur market expansion in the near future. Glycomics techniques are becoming more widely used as a result of government bodies sponsoring specific organizations to collaborate with academic institutions.
Biopharmaceutical Companies segment is anticipated to register rapid growth in forecast period, Segment expansion is anticipated to be supported by factors like growing efforts by biopharmaceutical companies to develop advanced therapeutics and large investments made by market players to adopt glycan-based methodologies in drug development.
North America occupied the largest market share in 2022:
North America has the largest revenue market share 39.10% in 2022, The presence of key players, advanced healthcare infrastructure, developed economies, and their various strategic initiatives collectively drive the market. The growth of the regional market can be attributed to rising research & development activities in the field of glycobiology and increasing prevalence of numerous types of personalized medicine and high consumer spending capacity on their health and well-being mainly in developed economies like the United States and Canada. Additionally, presence of key pharmaceutical and biopharmaceutical companies, accessibility to advanced products and presence of well-established healthcare infrastructure within the region.
On the other hand, Europe accounted for the significant share over the forecast period, The presence of world-class universities and research institutes, along with a supportive research infrastructure and high disease burden, are expected to drive the regional market. Furthermore, the availability of funding programs and research grants has enabled academic institutions and biopharmaceutical companies to carry out more thorough glycomics studies and investigate possible healthcare applications.
List of the prominent players in the Glycomics Market:
- Thermo Fisher Scientific, Inc.
- Merck KgaA
- Agilent Technologies Inc.
- New England Biolabs
- Shimadzu Corporation
- Waters Corporation
- Takara Bio Inc
- Asparia Glycomics
- RayBiotech Life, Inc.
Segmentation Analysis of the Glycomics Market
- Drug Discovery and Development
- Academic & Research Institute
- Pharmaceutical & Biotechnology Companies
- Biopharmaceutical Companies
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Impact of the COVID-19 Pandemic on the Glycomics Market:
It is projected that the growing number of people with chronic illnesses will spur the global glycomics market's expansion. In the next years, there should be plenty of growth opportunities for the market. The global glycomics market is being driven by the growing presence of research institutes and pharmaceutical companies to support the drug discovery and development sector. Developments in this area have been crucial to the study of drugs during the coronavirus pandemic. Amidst the pandemic in the global market, technological advancements in biotechnology, investments in research and development activities to study glycans’ or polysaccharides, and growing applications in disease diagnostics are creating revenue opportunities. As a result of the increased research, technology was used extensively in place of human resources to stop the spread of SARS-CoV-2. Additionally, initiatives and open challenge events were arranged by the governments of the Asia-Pacific region to encourage researchers to create novel COVID-19 treatment drugs. Due to increased government funding, these events led to an increase in COVID-19 research overall.